Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Amling

Showing results (51-60 of 199) with videos related to

Pageof 20
Sort By:
Urology|April 17, 2010
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH databaseChristopher J Kane, Ronald Im, Christopher L Amling, et al.
The Prostate|August 6, 2010
Glycemic control and prostate cancer progression: results from the SEARCH databaseHoward S Kim, Joseph C Presti, William J Aronson, et al.
BJU International|June 25, 2009
Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database GroupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
European Urology|December 19, 2012
Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Urology|June 29, 2013
Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
Urology|December 15, 2010
Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
BJU International|November 19, 2011
Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Urology|March 27, 2012
Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH databaseRoberto L Muller, Joseph C Presti, William J Aronson, et al.
The Journal of Urology|January 13, 2006
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detectionStephen J Freedland, Elizabeth A Platz, Joseph C Presti, et al.
The Journal of Urology|September 18, 2009
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH databaseDaniel M Moreira, Joseph C Presti, William J Aronson, et al.
Pageof 20

Showing results (51-60 of 199) with videos related to

Sort By:
Pageof 20
Urology|April 17, 2010
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH databaseChristopher J Kane, Ronald Im, Christopher L Amling, et al.
The Prostate|August 6, 2010
Glycemic control and prostate cancer progression: results from the SEARCH databaseHoward S Kim, Joseph C Presti, William J Aronson, et al.
BJU International|June 25, 2009
Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database GroupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
European Urology|December 19, 2012
Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Urology|June 29, 2013
Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
Urology|December 15, 2010
Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
BJU International|November 19, 2011
Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Urology|March 27, 2012
Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH databaseRoberto L Muller, Joseph C Presti, William J Aronson, et al.
The Journal of Urology|January 13, 2006
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detectionStephen J Freedland, Elizabeth A Platz, Joseph C Presti, et al.
The Journal of Urology|September 18, 2009
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH databaseDaniel M Moreira, Joseph C Presti, William J Aronson, et al.
Pageof 20